Working... Menu
Trial record 16 of 75 for:    "Collagen Disease" | "Triamcinolone"

Repeat Injection of Cingal® for Osteoarthritis of the Knee

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02381652
Recruitment Status : Completed
First Posted : March 6, 2015
Last Update Posted : June 22, 2015
Information provided by (Responsible Party):
Anika Therapeutics, Inc.

Brief Summary:
The objective of this study is to evaluate the safety of a repeat injection of Cingal® in subjects with Osteoarthritis (OA) of the knee who participated in Cingal 13-01. This will be done through examination of the incidence of adverse events and physical examination of the knee.

Condition or disease Intervention/treatment Phase
Osteoarthritis of the Knee Device: Cingal® Phase 3

Detailed Description:
The Cingal 13-02 study is a follow-on study to the recently completed clinical trial Cingal 13-01. Cingal 13-01 was a multi-center, randomized, double-blind, Phase III study that enrolled 368 subjects at up to 30 sites in Canada and Europe. The Cingal 13-01 study objective was to assess the safety and effectiveness of a single injection of Cingal® for relief of joint pain and symptoms in patients with OA of the knee. The study had three arms: the Cingal® investigational arm, an active comparator arm (Monovisc®) and a control arm (saline). Cingal 13-02 is designed to evaluate the safety of an open-label injection of Cingal® in subjects who received a study injection in the Cingal 13-01 trial.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 242 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Cingal 13-02: An Open-Label, Follow-On Study to Cingal 13-01 to Evaluate the Safety of a Repeat Injection of Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal®) to Provide Symptomatic Relief of Osteoarthritis of the Knee
Study Start Date : February 2015
Actual Primary Completion Date : April 2015
Actual Study Completion Date : May 2015

Arm Intervention/treatment
Experimental: Cingal®
Subjects will receive a single injection of Cingal® (Hyaluronic Acid plus Triamcinolone Hexacetonide)
Device: Cingal®
Injection into the knee
Other Name: Hyaluronic Acid with Triamcinolone Hexacetonide

Primary Outcome Measures :
  1. Safety Comparison of Adverse Event Profile of Cingal 13-02 vs. Cingal 13-01 [ Time Frame: Baseline through 6 weeks post-injection ]

    The following specific safety measures will be compared between the Cingal 13-01 results and the Cingal 13-02 results:

    1. All adverse events, whether related to the study injection or not
    2. All adverse events considered related to the study injection (definitely, probably, or possibly)
    3. 'Most common' adverse events related to the study injection that have an incidence rate > 5% (examples could be injection site pain, swelling, effusion, redness)
    4. Serious Adverse Events
    5. Serious Adverse Device Effects
    6. Unexpected Adverse Device Effects
    7. Physical exam findings (examples redness, swelling, effusion)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subject completed Cingal 13-01 and is interested in participating in the follow-on study
  2. Subject must be willing to abstain from other intra-articular or surgical treatments of the index knee for the duration of the study
  3. Subject is willing to discontinue all analgesics except acetaminophen/paracetamol for the duration of the study
  4. Subject is willing to use only acetaminophen/paracetamol (up to a maximum of 4.0 grams per day per the package insert) for the treatment of joint pain for the duration of the study. At least twenty-four hours prior to the injection and each follow-up visit, the subject is willing to discontinue use of acetaminophen/paracetamol
  5. Subject is able to understand and comply with the requirements of the study and voluntarily provides consent

Exclusion Criteria:

  1. Subject received an intra-articular injection or underwent a surgical procedure of the index knee since the study injection in Cingal 13-01
  2. Subject is taking medication at the time of consent which could interfere with the treatment procedure, healing and/or assessments. This includes but is not limited to oral or injectable anticoagulant treatments, anti-aggregant platelet treatment and opioid analgesics. Low dose aspirin used for cardiovascular protection is allowed if a stable regimen is maintained for the duration of the study.
  3. Subjects who had an oral, intramuscular, intravenous, rectal suppository or topical (excluded in index knee only) corticosteroid within 30 days of signing the ICF are excluded. Topical corticosteroid use at any site other than the index knee is allowed.
  4. Subject has a contraindication to IA injections, aspiration of the index knee, corticosteroids, hyaluronan, or acetaminophen/paracetamol.
  5. Subject is pregnant or breastfeeding or a woman of child bearing potential who refuses to use effective contraception during the course of the study.
  6. Subject participated in a research study other than Cingal 13-01 within 60 days of consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02381652

Layout table for location information
Czech Republic
Medical Plus s.r.o.
Uherske Hradiste, Czech Republic
Belvaros-Lipotvaros, Orthopedic Outpatient Clinic
Budapest, Hungary
Semmelweis University, Department of Orthopaedics
Budapest, Hungary
Uzsoki Hospital, Department of Traumatology
Budapest, Hungary
Jutrix Healthcare Services Ltd.
Kecskemet, Hungary
Medidea Bt.
Kiskunfelegyhaza, Hungary
G&V Pharma-Med Bt.
Mako, Hungary
NZOZ Medi-Spatz
Gliwice, Poland
ARTIMED Niepubliczny Zaklad Opieki Zdrowotnej w Kielcach
Kielce, Poland
CenterMed Krakow Sp. z o.o.
Krakow, Poland
Sponsors and Collaborators
Anika Therapeutics, Inc.
Layout table for investigator information
Principal Investigator: Laszlo Hangody, MD, PhD, DSc Semmelweis University, Head of Department of Traumatology; Péterfy Sándor Hospital, Director of Traumatology Center; Uzsoki Hospital, Head of Department of Orthopedics
Principal Investigator: Piotr Lukasik, MD, PhD NZOZ Medi-Spatz

Layout table for additonal information
Responsible Party: Anika Therapeutics, Inc. Identifier: NCT02381652     History of Changes
Other Study ID Numbers: Cingal 13-02
First Posted: March 6, 2015    Key Record Dates
Last Update Posted: June 22, 2015
Last Verified: June 2015

Additional relevant MeSH terms:
Layout table for MeSH terms
Rheumatic Diseases
Triamcinolone Acetonide
Triamcinolone hexacetonide
Triamcinolone diacetate
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Hyaluronic Acid
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Immunosuppressive Agents
Immunologic Factors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Adjuvants, Immunologic
Protective Agents